Clinical trial • Phase III • Infectious Disease
Clinical trial in Invasive Aspergillosis
Phase III trial for Invasive Aspergillosis. 20 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Invasive Aspergillosis
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 26-08-2024
- First CTIS Authorization Date
- 20-12-2024
Trial design
Phase III trial across 1 site in Austria.
- Target Sample Size
- 20
Eligibility
Recruits 20 Vulnerable populations not selected (isVulnerablePopulationSelected: false). No specific consent or assent handling details provided in the record..
- Vulnerable Population
- Vulnerable populations not selected (isVulnerablePopulationSelected: false). No specific consent or assent handling details provided in the record.
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 62
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
Austria
- Earliest CTIS Part Ii Submission Date
- 21-11-2024
- Latest Decision Or Authorization Date
- 21-11-2025
- Processing Time Days
- 365
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- Waehringer Guertel 18-20, Alsergrund
- Department Name
- Department of Clinical Pharmacology
- Principal Investigator Name
- Markus Zeitlinger
- Principal Investigator Email
- markus.zeitlinger@meduniwien.ac.at
- Contact Person Name
- Markus Zeitlinger
- Contact Person Email
- markus.zeitlinger@meduniwien.ac.at
- Number Of Participants
- 20
Sponsor
Primary sponsor
- Full Name
- Medical University Of Vienna
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Austria
Related trials
Other published trials that may interest you.
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis
- AMIKACIN SULFATE for Sepsis | Neutropenia
- LENACAPAVIR, ISLATRAVIR for HIV-1 infection
- piperacillin sodium, tazobactam sodium for Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae severe infection